Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dialysis heavyweights punch well in second quarter

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences says net sales increased by 4%, excluding the effect of foreign exchange and divested businesses. In the company's cardiac surgery division, sales were $85 million, up 10%. Growth continues to be led by robust sales of its pericardial tissue valve products. Critical care sales rose 7% to $54 million. Edwards says it is benefiting from the continued trend of customers to more advanced technology catheter products. Vascular sales fell 3% to $13 million. The company says it is on track to re-enter the European market with its Lifepath AAA Endovascular graft system, as well as resuming US clinical trials of the product, by the end of the year. Edwards voluntarily halted European sales and US clinical trials of the device after it found a fracture in the product's wireform in April 2000 (see Clinica No 906, p 1). Edwards expects a 20% increase in net income for the full year.

You may also be interested in...

Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK

The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts